{
    "clinical_study": {
        "@rank": "31891", 
        "acronym": "IMAGINE", 
        "arm_group": {
            "arm_group_label": "LUM001", 
            "arm_group_type": "Experimental", 
            "description": "LUM001 administered orally once each day"
        }, 
        "brief_summary": {
            "textblock": "This is a multicentre, extension study of LUM001 in children diagnosed with Alagille\n      Syndrome who have completed participation in a core LUM001 treatment protocol. The primary\n      objective is to evaluate long-term safety and tolerability of LUM001.  Efficacy will be\n      assessed by evaluating the effect of LUM001 on the biochemical markers and pruritus\n      associated with Alagille Syndrome."
        }, 
        "brief_title": "An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Alagille Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Liver Diseases", 
                "Alagille Syndrome", 
                "Cholestasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Completed a core treatment protocol of LUM001 in the treatment of cholestatic liver\n             disease in pediatric subjects with Alagille Syndrome\n\n          2. Ability to understand and willingness to sign informed consent/assent prior to\n             initiation of any study procedures.\n\n        Exclusion Criteria:\n\n          1. Experienced an adverse event or serious adverse event related to the study drug\n             during a core LUM001 treatment protocol that led to the discontinuation of the\n             subject from the core LUM001 treatment study\n\n          2. History of non-adherence during the subject's participation in the core LUM001\n             treatment protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "12 Months"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047318", 
            "org_study_id": "LUM001-303"
        }, 
        "intervention": {
            "arm_group_label": "LUM001", 
            "intervention_name": "LUM001", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 16, 2014", 
        "link": {
            "url": "http://www.lumenapharma.com"
        }, 
        "location": [
            {
                "contact": {
                    "email": "carla.lloyd@bch.nhs.uk", 
                    "last_name": "Carla Lloyd"
                }, 
                "contact_backup": {
                    "email": "fazeelat.sharif@bch.nhs.uk", 
                    "last_name": "Fazeelat Sharif"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom", 
                        "state": "West Midlands", 
                        "zip": "B4 6NH"
                    }, 
                    "name": "Birmingham Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Deidre Kelly, FRCPI, FRCP,FRCPCH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nicola.balatoni@leedsth.nhs.uk", 
                    "last_name": "Nicola Balatoni"
                }, 
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom", 
                        "state": "West Yorkshire", 
                        "zip": "LS9 7TF"
                    }, 
                    "name": "Leeds Teaching Hospital"
                }, 
                "investigator": {
                    "last_name": "Patricia McClean, MD,FRCP,FRCPCH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pkarthikeyan@nhs.net", 
                    "last_name": "Palaniswamy Karthikeyan"
                }, 
                "contact_backup": {
                    "email": "denise.holley@nhs.net", 
                    "last_name": "Denise Holley"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE5 9RS"
                    }, 
                    "name": "Kings College Hospital"
                }, 
                "investigator": {
                    "last_name": "Alastair Baker, MBChB,FFARCS,MRCP,FRCPCH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicentre Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome", 
        "overall_contact": {
            "email": "info@lumenapharma.com", 
            "last_name": "Sara Barbat", 
            "phone": "858-461-0694"
        }, 
        "overall_official": {
            "affiliation": "Lumena Pharmaceuticals, Inc.", 
            "last_name": "Alejandro Dorenbaum, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adverse events, changes in vital signs, laboratory and other safety parameters from baseline to week 48", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047318"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Changes in serum bile acids, pruritus, and other biochemical markers of cholestasis and liver disease from baseline to week 48", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "48 weeks"
        }, 
        "source": "Lumena Pharmaceuticals, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Childhood Liver Disease Research and Education Network", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Lumena Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}